Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHABET Study
2024-514611-98-00Phase 3Completed
- Sponsor
- GEICAM
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of alpelisib in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Progression-free survival (PFS). Started Oct 2024; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514611-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514611-98-00.